ChromaDex Corporation (CDXC)
After hours:
| Previous close | 3.7900 |
| Open | 3.7800 |
| Bid | 3.6500 x 100 |
| Ask | 3.7500 x 100 |
| Day's range | 3.6100 - 3.9000 |
| 52-week range | 1.2500 - 4.6500 |
| Volume | |
| Avg. volume | 297,450 |
| Market cap | 277.891M |
| Beta (5Y monthly) | 1.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
LOS ANGELES, March 26, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAGEN
- Business Wire
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
LOS ANGELES, March 06, 2024--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.
- Business Wire
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
LOS ANGELES, February 21, 2024--ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
